Product Information


Product name

Dasatinib

Molecular Formula

C22H28CIN7O3S

Molecular Weight

506.02

CAS No.

302962-49-8

Quality Standard

USP26, EP, medical grade

Appearance

White powder


COA of Dasatinib


ITEMS

SPECIFICATION

RESULTS

IDENTIFICATION

POSITIVE REACTION

CONFORMS

Water

≤1.5%

0.9%

LOSS ON DRYING

≤0.1%

0.03%

RESIDUE ON IGNITION

≤0.1%

0.02%

CHROMATOGRAPHIC PURITY

RANITIDINE RELATED COMPOUND B≤0.5%

ANY OTHER IMPURITY≤0.3%

THE SUM OF ALL IMPURITIES≤1.0%

CONFORMS

CONFORMS

CONFORMS

ORGANIC VOLATILE IMPURITIES

AS STIPULATED

CONFORMS

ASSAY

(ON DRY SUBSTANCE)

98.0%~102.0%

99.8%

CONCLUSION

CONFORMS TO in house


Usage


Function of Dasatinib

Dasatinib (DASA tin IB), used for all treatment stages (chronic phase, accelerated phase) Stage, lymphoid cell blast crisis and myeloid blast crisis) adult patients. At the same time, the FDA also approved Dasatinib through normal procedures to treat Philadelphia chromosome-positive acute lymphoblastic leukemia adult patients who are resistant or intolerant to other therapies.

Dasatinib inhibits BCR-ABL kinase and SRC family kinases as well as many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase and PDGFβ receptor. Dasatinib is a potent, subnanomolar BCR-ABL kinase inhibitor with a strong activity at a concentration of 0.6 to 0.8 nmol. It can be combined with the inactive and active configurations of the BCR-ABL enzyme.

In vitro studies, dasatinib is active in leukemia cell lines expressing various imatinib-sensitive and drug-resistant diseases. The results of these non-clinical studies indicate that dasatinib can overcome imatinib resistance caused by: BCR-ABL overexpression, BCR-ABL kinase region mutations, kinases including SRC family kinases (LYN, HCK) in Over-expression of other signaling pathways within, as well as multidrug resistance genes. In addition, dasatinib can inhibit SRC family kinases at this nanomolar concentration

In an in vivo experiment conducted using the murine CML model alone, dasatinib prevented the progression of chronic phase CML to the acute phase, while prolonging tumor-bearing mice (derived from patient CML cell lines growing in different locations, including the central Nervous system)


Product Tags apis          api          apis google          apie bluetooth          florfenicol api          apis usa          api java          active api          smartthings api         

INQUIRY

Contact us for all information about the product


click here to leave a message

leave a message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.